Cisplatin-resistant prostate cancer model: Differences in antioxidant system, apoptosis and cell cycle

  • Authors:
    • Jaromir Gumulec
    • Jan Balvan
    • Marketa Sztalmachova
    • Martina Raudenska
    • Veronika Dvorakova
    • Lucia Knopfova
    • Hana Polanska
    • Kristyna Hudcova
    • Branislav Ruttkay-Nedecky
    • Petr Babula
    • Vojtech Adam
    • Rene Kizek
    • Marie Stiborova
    • Michal Masarik
  • View Affiliations

  • Published online on: December 20, 2013     https://doi.org/10.3892/ijo.2013.2223
  • Pages: 923-933
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Differences in the antioxidant system, apoptotic mechanism and in cell cycle between prostatic cell lines could partially elucidate the development of cisplatin resistance. The aim of this study was to identify the most characteristic parameter for a particular cell line and/or a particular cisplatin treatment using a general regression model and to assess whether it is possible to use measured parameters as markers of cisplatin resistance. This study integrates the results of viability, antioxidant, flow cytometric and quantitative PCR assays in order to characterize the resistance of prostate cancer to cisplatin. Cell growth using metabolic- (MTT) and impedance-based assays, the expression of key cell death signaling proteins (p53, Bax and Bcl-2), cell cycle, activity of antioxidant system-related proteins (superoxide dismutase, glutathione peroxidase, glutathione reductase and metallothionein) and free radical scavenging capacity assays [free radicals (FR), ferric reducing antioxidant power (FRAP), ABTS] were analyzed in the cell lines 22Rv1, PC-3 and PNT1A with respect to rising concentrations (0-150 µM) and different length of cisplatin treatment (12-72 h). The non-functional-p53 PC-3 cell line showed decreased BAX (p<0.05) and, in contrast to PNT1A and 22Rv1, no cisplatin-induced effects on cell cycle. All cell lines showed increasing levels of free radical scavenging activity by ABTS, FRAP and FR assays in a time- and dose-dependent manner (r>0.76 at p<0.001 for ABTS, FRAP and FR at p<0.001). PC-3 showed increased (p<0.05) levels of free radical scavenging activity by ABTS and FR methods. These findings, together with significantly elevated MT, decreased p53 and Bax indicate PC-3 to be cisplatin-resistant. The differences in the antioxidant system and apoptotic mechanisms in PC-3 cells may elucidate the development of cisplatin resistance and indicate that this cell line may be further studied as a model of cytostatic resistance.
View Figures
View References

Related Articles

Journal Cover

2014-March
Volume 44 Issue 3

Print ISSN: 1019-6439
Online ISSN:1791-2423

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Gumulec J, Balvan J, Sztalmachova M, Raudenska M, Dvorakova V, Knopfova L, Polanska H, Hudcova K, Ruttkay-Nedecky B, Babula P, Babula P, et al: Cisplatin-resistant prostate cancer model: Differences in antioxidant system, apoptosis and cell cycle. Int J Oncol 44: 923-933, 2014.
APA
Gumulec, J., Balvan, J., Sztalmachova, M., Raudenska, M., Dvorakova, V., Knopfova, L. ... Masarik, M. (2014). Cisplatin-resistant prostate cancer model: Differences in antioxidant system, apoptosis and cell cycle. International Journal of Oncology, 44, 923-933. https://doi.org/10.3892/ijo.2013.2223
MLA
Gumulec, J., Balvan, J., Sztalmachova, M., Raudenska, M., Dvorakova, V., Knopfova, L., Polanska, H., Hudcova, K., Ruttkay-Nedecky, B., Babula, P., Adam, V., Kizek, R., Stiborova, M., Masarik, M."Cisplatin-resistant prostate cancer model: Differences in antioxidant system, apoptosis and cell cycle". International Journal of Oncology 44.3 (2014): 923-933.
Chicago
Gumulec, J., Balvan, J., Sztalmachova, M., Raudenska, M., Dvorakova, V., Knopfova, L., Polanska, H., Hudcova, K., Ruttkay-Nedecky, B., Babula, P., Adam, V., Kizek, R., Stiborova, M., Masarik, M."Cisplatin-resistant prostate cancer model: Differences in antioxidant system, apoptosis and cell cycle". International Journal of Oncology 44, no. 3 (2014): 923-933. https://doi.org/10.3892/ijo.2013.2223